膦甲酸钠用于抑制人类免疫缺陷病毒复制。
Foscarnet for suppression of human immunodeficiency virus replication.
作者信息
Fletcher C V, Collier A C, Rhame F S, Bennett D, Para M F, Beatty C C, Jones C E, Balfour H H
机构信息
Department of Pharmacy Practice, University of Minnesota, Minneapolis.
出版信息
Antimicrob Agents Chemother. 1994 Mar;38(3):604-7. doi: 10.1128/AAC.38.3.604.
Abstract
The effect of foscarnet against human immunodeficiency virus (HIV) was evaluated in nine HIV-infected individuals; six completed 28 days of induction therapy. The overall mean increase in CD4+ lymphocytes was 64 cells per mm3. The mean decline in the HIV antigen concentration was 108 pg/ml (P = 0.03), and suppression was related to systemic foscarnet exposure by a maximum-effect pharmacodynamic model.
摘要
对9名感染人类免疫缺陷病毒（HIV）的个体评估了膦甲酸钠对HIV的疗效；其中6人完成了28天的诱导治疗。CD4+淋巴细胞的总体平均增加量为每立方毫米64个细胞。HIV抗原浓度的平均下降量为108 pg/ml（P = 0.03），并且通过最大效应药效学模型，抑制作用与全身膦甲酸钠暴露相关。
相似文献
1
Foscarnet for suppression of human immunodeficiency virus replication.膦甲酸钠用于抑制人类免疫缺陷病毒复制。
Antimicrob Agents Chemother. 1994 Mar;38(3):604-7. doi: 10.1128/AAC.38.3.604.
2
Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDS.膦甲酸钠对艾滋病患者血液中巨细胞病毒和人类免疫缺陷病毒数量的影响。
Antimicrob Agents Chemother. 1996 Dec;40(12):2721-6. doi: 10.1128/AAC.40.12.2721.
3
Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections.膦甲酸钠。对其在免疫功能低下的病毒感染患者中的抗病毒活性、药代动力学特性及治疗用途的重新评估。
Drugs. 1994 Aug;48(2):199-226. doi: 10.2165/00003495-199448020-00007.
4
Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.齐多夫定用于无症状人类免疫缺陷病毒感染。对每立方毫米CD4阳性细胞少于500个的患者进行的对照试验。美国国立过敏与传染病研究所艾滋病临床试验组。
N Engl J Med. 1990 Apr 5;322(14):941-9. doi: 10.1056/NEJM199004053221401.
5
The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.齐多夫定（AZT）治疗轻度症状的1型人类免疫缺陷病毒（HIV）感染患者的安全性和有效性。一项双盲、安慰剂对照试验。艾滋病临床试验组。
Ann Intern Med. 1990 May 15;112(10):727-37. doi: 10.7326/0003-4819-112-10-727.
6
Foscarnet salvage therapy for patients with late-stage HIV disease and multiple drug resistance.膦甲酸钠挽救疗法用于晚期HIV疾病和多重耐药患者。
Antivir Ther. 2006;11(5):561-6.
7
High-level viremia in adults and children infected with human immunodeficiency virus: relation to disease stage and CD4+ lymphocyte levels.
J Infect Dis. 1991 Jul;164(1):72-80. doi: 10.1093/infdis/164.1.72.
8
Pharmacodynamic relationship of pharmacokinetic parameters of maintenance doses of foscarnet and clinical outcome of cytomegalovirus retinitis.膦甲酸钠维持剂量的药代动力学参数与巨细胞病毒性视网膜炎临床结果的药效学关系。
Antimicrob Agents Chemother. 1994 May;38(5):1190-3. doi: 10.1128/AAC.38.5.1190.
9
Salvage Therapy Including Foscarnet and Ibalizumab for Multidrug-Resistant Human Immunodeficiency Virus Type 2 Infection.挽救治疗包括膦甲酸钠和ibalizumab 用于治疗多种药物耐药的人类免疫缺陷病毒 2 型感染。
Clin Infect Dis. 2024 Apr 10;78(4):1005-1010. doi: 10.1093/cid/ciad695.
10
[Prognostic indices for the course of HIV infection].
Verh Dtsch Ges Inn Med. 1991;97:386-90.
引用本文的文献
1
Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper.危重症成人患者的抗菌治疗药物监测：立场文件。
Intensive Care Med. 2020 Jun;46(6):1127-1153. doi: 10.1007/s00134-020-06050-1. Epub 2020 May 7.
2
Alkylglycerol prodrugs of phosphonoformate are potent in vitro inhibitors of nucleoside-resistant human immunodeficiency virus type 1 and select for resistance mutations that suppress zidovudine resistance.膦甲酸的烷基甘油前药是对核苷耐药的1型人类免疫缺陷病毒有效的体外抑制剂，并选择抑制齐多夫定耐药性的耐药突变。
Antimicrob Agents Chemother. 2001 Jun;45(6):1621-8. doi: 10.1128/AAC.45.6.1621-1628.2001.
3
Coresistance to zidovudine and foscarnet is associated with multiple mutations in the human immunodeficiency virus type 1 reverse transcriptase.对齐多夫定和膦甲酸的协同耐药与人类免疫缺陷病毒1型逆转录酶的多个突变相关。
Antimicrob Agents Chemother. 1998 Nov;42(11):3038-43. doi: 10.1128/AAC.42.11.3038.
4
Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDS.膦甲酸钠对艾滋病患者血液中巨细胞病毒和人类免疫缺陷病毒数量的影响。
Antimicrob Agents Chemother. 1996 Dec;40(12):2721-6. doi: 10.1128/AAC.40.12.2721.
5
Treatment of HIV infection. Tolerability of commonly used antiretroviral agents.HIV感染的治疗。常用抗逆转录病毒药物的耐受性。
Drug Saf. 1996 Sep;15(3):176-87. doi: 10.2165/00002018-199615030-00003.
6
Synergistic inhibition of human immunodeficiency virus isolates (including 3'-azido-3'-deoxythymidine-resistant isolates) by foscarnet in combination with 2',3'-dideoxyinosine or 2',3'-dideoxycytidine.膦甲酸钠与2'，3'-双脱氧肌苷或2'，3'-双脱氧胞苷联合对人免疫缺陷病毒分离株（包括对3'-叠氮-3'-脱氧胸苷耐药的分离株）的协同抑制作用。
Antimicrob Agents Chemother. 1996 May;40(5):1285-8. doi: 10.1128/AAC.40.5.1285.
7
Foscarnet alters antidiuretic hormone-mediated transport.膦甲酸钠改变抗利尿激素介导的转运。
Antimicrob Agents Chemother. 1995 Sep;39(9):2008-12. doi: 10.1128/AAC.39.9.2008.
8
Liposomal encapsulation of foscarnet protects against hypocalcemia induced by free foscarnet.膦甲酸钠的脂质体包封可防止游离膦甲酸钠引起的低钙血症。
Antimicrob Agents Chemother. 1995 Sep;39(9):1973-8. doi: 10.1128/AAC.39.9.1973.
9
Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates.1型人类免疫缺陷病毒逆转录酶中的新型突变降低了实验室和临床分离株对膦甲酸钠的敏感性。
Antimicrob Agents Chemother. 1995 May;39(5):1087-92. doi: 10.1128/AAC.39.5.1087.
10
Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections.膦甲酸钠。对其在免疫功能低下的病毒感染患者中的抗病毒活性、药代动力学特性及治疗用途的重新评估。
Drugs. 1994 Aug;48(2):199-226. doi: 10.2165/00003495-199448020-00007.
本文引用的文献
1
Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.理解剂量-效应关系：药代动力学-药效学模型的临床应用
Clin Pharmacokinet. 1981 Nov-Dec;6(6):429-53. doi: 10.2165/00003088-198106060-00002.
2
Simulation of linear compartment models with application to nuclear medicine kinetic modeling.线性房室模型的模拟及其在核医学动力学建模中的应用。
Comput Methods Programs Biomed. 1988 Jul-Aug;27(1):47-54. doi: 10.1016/0169-2607(88)90102-2.
3
Pharmacokinetics and absorption of foscarnet after intravenous and oral administration to patients with human immunodeficiency virus.
Clin Pharmacol Ther. 1988 Jul;44(1):65-73. doi: 10.1038/clpt.1988.114.
4
Effect of Foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS.膦甲酸钠疗法对艾滋病患者感染人类免疫缺陷病毒的影响。
J Infect Dis. 1988 Oct;158(4):862-5.
5
Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis.间歇性静脉注射膦甲酸钠治疗获得性免疫缺陷综合征合并严重巨细胞病毒性视网膜炎患者的药代动力学
Antimicrob Agents Chemother. 1989 May;33(5):742-5. doi: 10.1128/AAC.33.5.742.
6
Pharmacokinetics of foscarnet and distribution to cerebrospinal fluid after intravenous infusion in patients with human immunodeficiency virus infection.膦甲酸钠在人类免疫缺陷病毒感染患者静脉输注后的药代动力学及脑脊液分布情况。
Antimicrob Agents Chemother. 1989 Jul;33(7):1023-31. doi: 10.1128/AAC.33.7.1023.
7
Inhibition of human immunodeficiency virus in vitro by combinations of 3'-azido-3'-deoxythymidine and foscarnet.3'-叠氮-3'-脱氧胸苷与膦甲酸联合用药在体外对人类免疫缺陷病毒的抑制作用
Antimicrob Agents Chemother. 1989 May;33(5):778-80. doi: 10.1128/AAC.33.5.778.
8
Determination of phosphonoformate (foscarnet) in biological fluids by ion-pair reversed-phase liquid chromatography.
J Chromatogr. 1989 Mar 24;488(2):447-55. doi: 10.1016/s0378-4347(00)82968-0.
9
Inhibition of human T-cell lymphotropic virus type III in vitro by phosphonoformate.
Lancet. 1985 Jun 29;1(8444):1480-2. doi: 10.1016/s0140-6736(85)92255-x.
10
A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS.一项关于膦甲酸钠治疗艾滋病患者巨细胞病毒性视网膜炎的随机对照试验。
Ann Intern Med. 1991 Nov 1;115(9):665-73. doi: 10.7326/0003-4819-115-9-665.
Zotero 插件